Specifically, we have started developing anti-AD candidate drugs to inhibit the GSK-3β/p-tau/Bax/caspase-3 pathways dependent on interference with miR-23b-3p (Li et al., 2023). This evidence concerns the gene MAPT and Alzheimer disease.